Smooth muscle relaxant. It has the function of inhibiting adenylate cyclase and phosphodiesterase, antagonizing calcium ions, and has a weak antimuscarinic effect. It has a selective antispasmodic effect on the smooth muscles of the urogenital system, and can directly relieve the spasm of the smooth muscles of the urogenital system, relax the muscles, and eliminate the lower abdominal pain caused by frequent urination, urgency, urinary incontinence, and spasm of the urethral bladder smooth muscles.

This product is an angiotensin II receptor (AT1 type) antagonist. It can block various pharmacological effects (including vasoconstriction, aldosterone release, etc.) produced by endogenous and exogenous angiotensin II. This product can selectively act on AT1 receptors, does not affect the functions of other hormone receptors or important ion channels in the cardiovascular system, does not inhibit angiotensin converting enzyme (kininase II) that degrades bradykinin, and does not affect the metabolic process of angiotensin II and bradykinin.

This product is an angiotensin II receptor (AT1 type) antagonist, which can block the corresponding physiological effects of angiotensin II synthesized from any source and any pathway. It selectively acts on the AT1 receptor, does not affect the functions of other hormone receptors or important ion channels in the cardiovascular system, and does not inhibit angiotensin converting enzyme (kininase II) that degrades bradykinin.

This product is a bone metabolism regulator, an aminobisphosphonate, which has a strong affinity with hydroxyapatite in the bone. It can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts. It is characterized by strong anti-bone resorption activity and no bone mineralization inhibition.

No specific pharmacological information is provided